Skip to content

Mounjaro side effects: what the label reports

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

The most common Mounjaro side effects in the label's placebo-controlled trials were nausea (12% to 18% across the three doses, 4% on placebo), diarrhea (12% to 17%), decreased appetite (5% to 11%), vomiting (5% to 9%) and constipation (6% to 7%). The trials enrolled adults with type 2 diabetes, exposed for a mean of 36.6 weeks. Tell your prescriber about signs of low blood sugar or dehydration.

Source: Mounjaro FDA label

Key takeaways

  • Nausea, diarrhea, decreased appetite, vomiting and constipation lead the table for adults with type 2 diabetes on Mounjaro.
  • Low blood sugar depends on your other medicines. Insulin or a sulfonylurea may raise the risk, including severe low blood sugar.
  • Mounjaro carries a boxed warning, the strongest kind the FDA requires, about thyroid C-cell tumors.
  • It must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
  • Call your prescriber about severe abdominal pain or dehydration. A serious allergic reaction needs urgent medical care.

How often it was reported in the label's trials

Mounjaro: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
ReactionPlacebon=2355 mgn=23710 mgn=24015 mgn=241
Nausea4%12%15%18%
Diarrhea9%12%13%17%
Decreased Appetite1%5%10%11%
Vomiting2%5%5%9%
Constipation1%6%6%7%
Dyspepsia3%8%8%5%
Abdominal Pain4%6%5%5%
Mounjaro: Table 2: Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Adult Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in the placebo-controlled monotherapy trial (40 weeks); percentage of patients reporting at least 1 episode.
ReactionPlacebon=1155 mgn=12110 mgn=11915 mgn=120
Blood glucose <54 mg/dL1%0%0%0%
Severe hypoglycemia0%0%0%0%
Mounjaro: Table 2: Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Adult Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in the placebo-controlled trial of Mounjaro added to basal insulin with or without metformin (40 weeks); percentage of patients reporting at least 1 episode.
ReactionPlacebon=1205 mgn=11610 mgn=11915 mgn=120
Blood glucose <54 mg/dL13%16%19%14%
Severe hypoglycemia0%0%2%1%
Mounjaro: Table 3: Hypoglycemia Adverse Reactions in the 30 Week Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus · Pediatric patients 10 years of age and older with type 2 diabetes in the 30-week trial, Mounjaro added to basal insulin with or without metformin; percentage of patients with at least 1 episode of blood glucose <54 mg/dL.
ReactionPlacebon=105 mgn=1010 mgn=11
Blood glucose <54 mg/dL10%30%27%
Mounjaro: Table 3: Hypoglycemia Adverse Reactions in the 30 Week Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus · Pediatric patients 10 years of age and older with type 2 diabetes in the 30-week trial, Mounjaro added to metformin alone; percentage of patients with at least 1 episode of blood glucose <54 mg/dL.
ReactionPlacebon=245 mgn=2210 mgn=22
Blood glucose <54 mg/dL4%9%9%

Mounjaro: Gastrointestinal adverse reactions

In the pool of placebo-controlled trials in adults, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%).

Mounjaro: Eructation, flatulence, reflux and abdominal distension

The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated adult patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).

Mounjaro: Hypoglycemia with a sulfonylurea

In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.

Mounjaro: Acute pancreatitis

In clinical studies, 14 events of acute pancreatitis were confirmed by adjudication in 13 MOUNJARO-treated adult patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure).

Mounjaro: Heart rate increase

In the pool of placebo-controlled trials in adults, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.

Mounjaro: Hypersensitivity reactions

Hypersensitivity reactions have been reported with MOUNJARO in the pool of placebo-controlled trials in adults, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of MOUNJARO-treated patients compared to 1.7% of placebo-treated patients.

Mounjaro: Injection site reactions

In the pool of placebo-controlled trials in adults, injection site reactions were reported in 3.2% of MOUNJARO-treated patients compared to 0.4% of placebo-treated patients.

Mounjaro: Acute gallbladder disease

In the pool of placebo-controlled clinical trials in adults, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients.

Mounjaro: Dysesthesia

In the pool of placebo-controlled clinical trials in adults, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo. In a CV outcomes trial, 0.7% of MOUNJARO-treated patients reported dysesthesia.

Mounjaro: Dysgeusia

In the pool of placebo-controlled clinical trials in adults, dysgeusia was reported by 0.1% of MOUNJARO-treated patients and 0% of placebo-treated patients.

Mounjaro: Amylase and lipase increase

In the pool of placebo-controlled clinical trials in adults, treatment with MOUNJARO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 33% to 38% and serum lipase concentrations of 31% to 42%. Placebo-treated patients had a mean increase from baseline in pancreatic amylase of 4% and no changes were observed in lipase.

Mounjaro: Cardiovascular outcomes trial adverse reactions

In a CV outcomes trial of 6,647 adults with type 2 diabetes mellitus and established CV disease exposed to MOUNJARO, adverse reactions reported with MOUNJARO were similar with the exception of dysesthesia (0.7%), decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%), and fatigue (10%) [see Clinical Studies (14.6)].

Mounjaro: Vomiting and abdominal pain in pediatric patients

During the 30-week placebo-controlled period of the study, vomiting occurred in 3%, 16%, and 12% of patients and abdominal pain occurred in 9%, 22%, and 15% of patients treated with placebo, MOUNJARO 5 mg, and 10 mg, respectively.

Mounjaro: Hair loss (alopecia), postmarketing

Skin and Subcutaneous Tissue: alopecia

FDA label: Mounjaro, Revised: 8/2026 (DailyMed version 40)

Warnings on the Mounjaro label

  • Risk of Thyroid C-Cell Tumors

    Tirzepatide caused thyroid C-cell tumors in rats, and it is not known whether Mounjaro causes them in people.

    In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures [see Nonclinical Toxicology (13.1)]. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
  • Acute Pancreatitis

    Inflammation of the pancreas, including fatal cases, has been observed, and Mounjaro should be stopped if pancreatitis is suspected.

    Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO [see Adverse Reactions (6)].
  • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

    Using Mounjaro together with insulin or a sulfonylurea may raise the risk of low blood sugar, including severe low blood sugar.

    Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1), Drug Interactions (7.1)].
  • Hypersensitivity Reactions

    Serious allergic reactions such as anaphylaxis and angioedema have been reported, and Mounjaro should be stopped if one occurs.

    Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with MOUNJARO. If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve.
  • Acute Kidney Injury Due to Volume Depletion

    Dehydration from nausea, vomiting or diarrhea has led to acute kidney injury in some patients.

    There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or MOUNJARO. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6)].
  • Severe Gastrointestinal Adverse Reactions

    Mounjaro can cause stomach and bowel side effects that are sometimes severe, and it is not recommended for people with severe gastroparesis.

    Use of MOUNJARO has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6)]. In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%).
  • Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy

    Rapid improvement in blood sugar has been linked to temporary worsening of diabetic retinopathy, so patients with a history of it should be monitored.

    Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
  • Acute Gallbladder Disease

    Gallbladder problems such as gallstones and gallbladder inflammation have been reported with GLP-1 medicines and in Mounjaro trials.

    Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation

    Because Mounjaro slows stomach emptying, there have been rare reports with GLP-1 medicines of stomach contents entering the lungs during anesthesia or deep sedation.

    MOUNJARO delays gastric emptying [see Clinical Pharmacology (12.2)]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
  • Never Share a MOUNJARO KwikPen Between Patients

    A Mounjaro KwikPen must never be shared between patients, even with a new needle, because of infection risk.

    Never share MOUNJARO KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.

If a side effect has you worried, tell your prescriber about signs of low blood sugar, above all if you also take insulin or a sulfonylurea, and about nausea, vomiting or diarrhea that leaves you dehydrated. Severe abdominal pain also needs a call. Signs of a serious allergic reaction need urgent medical care. Dose changes are your prescriber’s decision.

Mounjaro is a type 2 diabetes medicine, and its label measures side effects in people with diabetes. The main table pools two placebo-controlled trials in adults: one of Mounjaro alone (SURPASS-1) and one of Mounjaro added to basal insulin (SURPASS-5). Basal insulin is long-acting insulin, and a placebo group gets an inactive treatment instead of the medicine. Together the trials exposed 718 patients to Mounjaro for a mean of 36.6 weeks.

What are the most common side effects of Mounjaro?

The label’s table lists seven reactions reported by at least 5% of Mounjaro patients. Figures are for 5 mg, 10 mg and 15 mg, then placebo.

  • Nausea: 12%, 15% and 18%, with 4% on placebo.
  • Diarrhea: 12%, 13% and 17%, with 9% on placebo.
  • Decreased appetite: 5%, 10% and 11%, with 1% on placebo.
  • Vomiting: 5%, 5% and 9%, with 2% on placebo.
  • Constipation: 6%, 6% and 7%, with 1% on placebo.
  • Dyspepsia (indigestion): 8%, 8% and 5%, with 3% on placebo.
  • Abdominal pain: 6%, 5% and 5%, with 4% on placebo.

Outside the table, the label reports injection site reactions in 3.2% of Mounjaro patients and 0.4% on placebo (see injection site reactions), and a mean increase in heart rate of 2 to 4 beats per minute.

How common are stomach side effects on Mounjaro?

Counted together, gastrointestinal (stomach and bowel) reactions were reported by 37.1% of patients at 5 mg, 39.6% at 10 mg and 43.6% at 15 mg, against 20.4% on placebo.

Severe gastrointestinal reactions were rare in these trials and didn’t track the dose: 1.3% at 5 mg, 0.4% at 10 mg and 1.2% at 15 mg, against 0.9% on placebo. The label says Mounjaro is not recommended in patients with severe gastroparesis (a stomach that empties very slowly).

Does Mounjaro cause low blood sugar?

It depends on what other diabetes medicines you take.

  • Mounjaro alone: no patient at any dose had blood glucose below 54 mg/dL, against 1% on placebo.
  • Added to basal insulin: 16%, 19% and 14% at the three doses, against 13% on placebo. Severe hypoglycemia (low blood sugar) occurred in 2% at 10 mg and 1% at 15 mg.
  • With a sulfonylurea, a type of diabetes pill, in a trial of up to 104 weeks: 13.8%, 9.9% and 12.8%, with severe hypoglycemia in 0.5%, 0% and 0.6%.

The label warns that combining Mounjaro with insulin or a sulfonylurea may increase the risk, including severe hypoglycemia. Adjusting those medicines is your prescriber’s call.

What did longer and pediatric trials show?

In a cardiovascular outcomes trial that exposed 6,647 adults with type 2 diabetes and established cardiovascular disease to Mounjaro, the label says reactions were similar, with exceptions: decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%) and fatigue (10%).

In the 30-week trial in patients aged 10 and older, vomiting occurred in 16% at 5 mg and 12% at 10 mg, against 3% on placebo. Abdominal pain occurred in 22% and 15%, against 9%.

What is the boxed warning, and what are the serious side effects?

Mounjaro carries a boxed warning for thyroid C-cell tumors. A boxed warning is the strongest kind the FDA requires, set apart in a box on the label. Tirzepatide causes these tumors in male and female rats, and the label says it’s unknown whether Mounjaro causes them, “including medullary thyroid carcinoma (MTC), in humans.” Mounjaro is contraindicated, meaning it must not be used, in patients with a personal or family history of MTC or with MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).

The label’s other warnings:

  • Acute pancreatitis (inflammation of the pancreas), including fatal cases with this class of medicines. Across clinical studies there were 14 confirmed events in 13 Mounjaro patients.
  • Serious allergic reactions such as anaphylaxis, a sudden and severe whole-body reaction, and angioedema, swelling under the skin. The label says to discontinue Mounjaro if one occurs.
  • Acute kidney injury, mostly in patients dehydrated by nausea, vomiting or diarrhea.
  • Acute gallbladder disease: 0.6% of Mounjaro patients and 0% on placebo.
  • Diabetic retinopathy (eye damage from diabetes): temporary worsening has been reported with rapid improvement in glucose control.
  • Pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation, and a warning never to share a Mounjaro KwikPen.

The label also lists alopecia (hair loss) among reactions reported after approval. The safety guide sets these warnings side by side for all the medicines.

How many people stop Mounjaro because of side effects?

The label gives the figure for stomach and bowel reactions: 3.0% of patients on 5 mg, 5.4% on 10 mg and 6.6% on 15 mg stopped treatment because of them, against 0.4% on placebo.

When to call your prescriber

The warnings show what a prescriber needs to hear about:

  • Signs of low blood sugar, above all if you also take insulin or a sulfonylurea.
  • Nausea, vomiting or diarrhea that leaves you dehydrated.
  • Severe abdominal pain. The label says Mounjaro should be stopped if pancreatitis is suspected.
  • Signs of a serious allergic reaction, which needs urgent medical care.
  • A history of diabetic retinopathy, or a planned procedure with anesthesia or deep sedation.

Dose changes are your prescriber’s decision, not something to settle alone. The Mounjaro guide covers the rest of the label, and the side effects guide compares each reaction across medicines.

Frequently asked questions

What are the most common side effects of Mounjaro?

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion) and abdominal pain. In the label's pool of two placebo-controlled trials in adults with type 2 diabetes, 12% of patients at 5 mg, 15% at 10 mg and 18% at 15 mg reported nausea, against 4% on placebo. Diarrhea was reported by 12%, 13% and 17%, against 9% on placebo.

Does Mounjaro cause low blood sugar?

It depends on what you take with it. In the trial of Mounjaro alone, no Mounjaro patient had blood glucose below 54 mg/dL. Added to basal (long-acting) insulin, 16% of patients at 5 mg, 19% at 10 mg and 14% at 15 mg did, against 13% on placebo. The label warns that insulin or a sulfonylurea may raise the risk, including severe low blood sugar.

Does Mounjaro cause hair loss?

Hair loss isn't in the Mounjaro trial table. The label lists alopecia (hair loss) among the reactions reported after approval, under skin and subcutaneous tissue, and gives no rate for it. Reports of that kind are voluntary, so they show that hair loss has been reported with Mounjaro, not how often it happens.

Is Mounjaro safe?

The label doesn't answer with a yes or a no. It carries a boxed warning, the strongest kind the FDA requires: tirzepatide causes thyroid C-cell tumors in rats, and it's unknown whether Mounjaro causes them in humans. Mounjaro must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Whether it suits you is a decision for your prescriber.

What are the serious side effects of Mounjaro?

The label's warnings cover acute pancreatitis, low blood sugar with insulin or a sulfonylurea, serious allergic reactions, acute kidney injury after dehydration, severe stomach and bowel reactions, worsening of diabetic retinopathy (eye damage from diabetes), acute gallbladder disease and pulmonary aspiration during anesthesia or deep sedation. Acute gallbladder disease was reported by 0.6% of Mounjaro patients in the placebo-controlled trials.

Sources (3)

  1. 1.
    FDA label (DailyMed): Mounjaro prescribing information, section 4
    “MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  2. 2.
    FDA label (DailyMed): Mounjaro prescribing information, section 5.6
    “MOUNJARO is not recommended in patients with severe gastroparesis.”
  3. 3.